Figure 4.

Cdc42 inhibition alters critical cellular processes. (a) Cdc42 regulators decrease cell proliferation. Relative cellular density of lung and prostate cancer cells up to 144 h after treatment with ZCL278, ZCL367, or AZA1. (b) Cdc42 inhibitors alter FBS-stimulated cell cycle progression. Relative cell cycle distribution of lung and prostate cancer cells after 24 h of starvation followed by 24 h FBS-stimulation with or without treatment (A549, HCC827, H522 = 50 μM ZCL367 or 10 μM AZA1; PC3, DU145, 22Rv1, LNCaP = 20 μM ZCL367 or 5 μM AZA1). (c) Effect of Cdc42 inhibitors on cell viability. Cells (5 × 10⁴)  were seeded and, after 24 h, treated with compound for 24 h. A solution of MTT was added and the reading was taken after 3 h. 50 μM NSC23766 (NSC), a Rac1 inhibitor, and 50 μM NSC + 50 μM ZCL367 is not as toxic as AZA1 alone. The absorbance was measured at 562 nm. All data are presented as mean±SEM from duplicates or triplicates from two independent experiments. ANOVA compared treatments to their respective control (* p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.0001).